Related Experiment Video

Updated: May 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer

Ivan Diaz-Padilla1, Ignacio Duran, Blaise A Clarke

  • 1Division of Medical Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada. ivan.padilla@uhn.on.ca

Cancer Treatment Reviews
|March 3, 2012
PubMed

Insights

Targeted therapies like mammalian target of rapamycin (mTOR) inhibitors offer new hope for advanced gynecological cancers. Research is exploring their effectiveness and resistance mechanisms to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced recurrent gynecological malignancies have a poor prognosis with current chemotherapy.
  • Mammalian target of rapamycin (mTOR) pathway is crucial for cancer cell growth and is frequently dysregulated in gynecological cancers.
  • Molecularly targeted therapies, including mTOR inhibitors, represent a promising treatment avenue.

Purpose of the Study:

  • To review clinical and biological data on first-generation mTOR inhibitors in gynecological tumors.
  • To discuss the molecular basis of sensitivity and resistance to mTOR inhibitors.
  • To explore potential combination regimens involving mTOR inhibitors for gynecological cancers.

Main Methods:

  • Literature review of clinical studies and biological data.
  • Analysis of the role of the PI3K/AKT/mTOR signaling pathway in gynecological cancers.
  • Discussion of emerging treatment strategies and combination therapies.

Main Results:

  • First-generation mTOR inhibitors have shown promising activity in endometrial cancer.
  • The molecular mechanisms of sensitivity and resistance to mTOR inhibitors are not fully understood.
  • Aberrant PI3K-dependent signaling is common in ovarian, endometrial, and cervical cancers.

Conclusions:

  • mTOR inhibitors are an important emerging option for advanced gynecological malignancies.
  • Further research is needed to elucidate resistance mechanisms and optimize treatment strategies.
  • Combination therapies with mTOR inhibitors may enhance efficacy in gynecological cancers.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...